METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cholesterol drug boosts immunotherapy against tough head and neck cancers
Disease control Recruiting nowThis study tests whether adding a common cholesterol-lowering drug (lovastatin) to an immunotherapy (pembrolizumab) can help shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has not responded to prior treatments will rece…
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 08:23 UTC
-
New combo therapy aims to shrink tough cancers using biomarker clues
Disease control Recruiting nowThis study tests two drugs—cabozantinib and nivolumab—in people with advanced melanoma or head and neck cancer that has stopped responding to other treatments. The goal is to see if the combination can shrink or stabilize the cancer, and whether certain tumor biomarkers can predi…
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:15 UTC
-
New combo therapy aims to outsmart tough head and neck cancers
Disease control Recruiting nowThis study tests whether adding cetuximab to the immunotherapy drug pembrolizumab helps people with advanced head and neck cancer live longer than pembrolizumab alone. The trial enrolls about 158 adults whose cancer has returned or spread and no longer responds to platinum chemot…
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New vaccine combo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with an immunotherapy drug (pembrolizumab), for head and neck cancer that has returned or spread. The study aims to find the safest dose and check for side effects in 40 adul…
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Mayo clinic launches large study to find throat cancer markers
Knowledge-focused Recruiting nowThis study aims to find biological markers (biomarkers) that show up in the blood, tissue, or saliva when a person has HPV-related throat cancer, and disappear after successful treatment. Researchers will collect samples from 560 adults with or without the cancer to compare. The …
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 26, 2026 08:23 UTC
-
Remote hearing tests could save cancer Patients' ears
Knowledge-focused Recruiting nowThis study looks at whether offering hearing tests close to home or online can help more head and neck cancer patients get their hearing checked during treatment. Chemotherapy and radiation can cause hearing loss, but many patients skip follow-up tests. The goal is to see if easi…
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 20, 2026 11:54 UTC